Yongjun Guan1, Hongbo Shi1, Tianlin Xiao1. 1. Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science China.
Abstract
OBJECTIVE: Prostate cancer is one of the most diagnosed malignancies in men worldwide. Novel (nua) kinase family 1 (NUAK1) is a member of adenosine monophosphate (AMP)-related kinase which participates in varying cancers progression. However, the role of NUAK1 in prostate tumorigenesis has not been fully characterized. The aim of this study was to elucidate the potential biological role of NUAK1 in prostate cancer. METHODS: Quantitative real-time PCR (qRT-PCR) was performed to determine the expression levels of NUAK1 and microRNA-30b-5p (miRNA-30b-5p) in prostate cancer cell lines and samples. Western blot was conducted to explore the related protein levels of epithelial-mesenchymal transition (EMT) and NUAK1 expression in prostate cancer cells. Trans-well test was used to assay prostate cancer cell migration and invasion. Luciferase assays were employed to probe the interaction between NUAK1 and miR-30b-5p. RESULTS: NUAK1 abundance was enhanced in prostate cancer tissues and cell lines. The knockdown of NUAK1 may inhibit prostate cancer cells EMT, migration and invasion. Luciferase assays suggested NUAK1 was a target gene of miR-30b-5p. Furthermore, miR-30b-5p suppressed EMT, migration, and invasion in prostate cancer cells and introduction of NUAK1 abated the inhibitory effect. CONCLUSIONS: Both of NUAK1 and miR-30b-5p were required for prostate cancer progression. NUAK1 interference limited prostate cancer cell EMT, migration and invasion by miRNA-30b-5p modulating, providing a promising therapeutic approach for prostate cancer. IJCEP
OBJECTIVE:Prostate cancer is one of the most diagnosed malignancies in men worldwide. Novel (nua) kinase family 1 (NUAK1) is a member of adenosine monophosphate (AMP)-related kinase which participates in varying cancers progression. However, the role of NUAK1 in prostate tumorigenesis has not been fully characterized. The aim of this study was to elucidate the potential biological role of NUAK1 in prostate cancer. METHODS: Quantitative real-time PCR (qRT-PCR) was performed to determine the expression levels of NUAK1 and microRNA-30b-5p (miRNA-30b-5p) in prostate cancer cell lines and samples. Western blot was conducted to explore the related protein levels of epithelial-mesenchymal transition (EMT) and NUAK1 expression in prostate cancer cells. Trans-well test was used to assay prostate cancer cell migration and invasion. Luciferase assays were employed to probe the interaction between NUAK1 and miR-30b-5p. RESULTS:NUAK1 abundance was enhanced in prostate cancer tissues and cell lines. The knockdown of NUAK1 may inhibit prostate cancer cells EMT, migration and invasion. Luciferase assays suggested NUAK1 was a target gene of miR-30b-5p. Furthermore, miR-30b-5p suppressed EMT, migration, and invasion in prostate cancer cells and introduction of NUAK1 abated the inhibitory effect. CONCLUSIONS: Both of NUAK1 and miR-30b-5p were required for prostate cancer progression. NUAK1 interference limited prostate cancer cell EMT, migration and invasion by miRNA-30b-5p modulating, providing a promising therapeutic approach for prostate cancer. IJCEP
Authors: Kasper Drimer Berg; Frederik Birkebæk Thomsen; Marta K Mikkelsen; Inga J Ingimarsdóttir; Rikke B Hansen; Anne Mette T Kejs; Klaus Brasso Journal: Eur J Cancer Date: 2016-12-23 Impact factor: 9.162
Authors: John T Helgstrand; Martin A Røder; Nina Klemann; Birgitte G Toft; Daphne Y Lichtensztajn; James D Brooks; Klaus Brasso; Ben Vainer; Peter Iversen Journal: Cancer Date: 2018-05-03 Impact factor: 6.860
Authors: Chen Liu; Teli Liu; Ning Zhang; Yiqiang Liu; Nan Li; Peng Du; Yong Yang; Ming Liu; Kan Gong; Xing Yang; Hua Zhu; Kun Yan; Zhi Yang Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-02 Impact factor: 9.236
Authors: Francesca Maria Orlandella; Raffaela Mariarosaria Mariniello; Peppino Mirabelli; Anna Elisa De Stefano; Paola Lucia Chiara Iervolino; Vito Alessandro Lasorsa; Mario Capasso; Rosa Giannatiempo; Maria Rongo; Mariarosaria Incoronato; Francesco Messina; Marco Salvatore; Andrea Soricelli; Giuliana Salvatore Journal: Br J Cancer Date: 2020-05-18 Impact factor: 7.640